relapsingg multiple sclerosis
Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis
May 31, 2019Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis
New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
